{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:22:17Z","timestamp":1777638137155,"version":"3.51.4"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Health Laboratory Service Research Trust"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.critrevonc.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T12:48:55Z","timestamp":1536929335000},"page":"17-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The role of Cancer\/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy"],"prefix":"10.1016","volume":"132","author":[{"given":"Karen","family":"Shires","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teagan","family":"Van Wyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2018.09.010_bib0005","article-title":"Ski-interacting protein interacts with androgen receptor in the nucleus and modulates androgen dependant transcription","volume":"14","author":"Abankwa","year":"2013","journal-title":"BMC Biochem."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.09.010_bib0010","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.3390\/ijms17091506","article-title":"Development of novel immunotherapies for multiple myeloma","volume":"17","author":"Al-hujaily","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"SUPPL. 1","key":"10.1016\/j.critrevonc.2018.09.010_bib0015","first-page":"2007","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0020","first-page":"2","article-title":"Prognostic impact of cancer\/testis antigen expression in advanced stage multiple myeloma patients","volume":"8","author":"Andrade","year":"2008","journal-title":"Cancer Immun."},{"issue":"28","key":"10.1016\/j.critrevonc.2018.09.010_bib0025","doi-asserted-by":"crossref","first-page":"21824","DOI":"10.1074\/jbc.M110.120600","article-title":"Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling","volume":"285","author":"Askew","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.09.010_bib0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2006-04-014480","article-title":"Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation","volume":"109","author":"Atanackovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2009.014464","article-title":"Cancer-testis antigens MAGE-C1\/CT7 and MAGE-A3 promote the survival of multiple myeloma cells","volume":"95","author":"Atanackovic","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0040","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1128\/MCB.25.4.1238-1257.2005","article-title":"Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction","volume":"25","author":"Bai","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.09.010_bib0050","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/sj.cdd.4400396","article-title":"The role of the tumor suppressor p53 in spermatogenesis","volume":"5","author":"Beumer","year":"1998","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.09.010_bib0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00109-009-0531-7","article-title":"Cancer stem cells: controversies in multiple myeloma","volume":"87","author":"Brennan","year":"2009","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0060","series-title":"Molecular Profiling in Multiple Myeloma","author":"Broyl","year":"2012"},{"issue":"11","key":"10.1016\/j.critrevonc.2018.09.010_bib0065","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/testis (CT) antigens: potential targets for immunotherapy","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer Sci."},{"issue":"20","key":"10.1016\/j.critrevonc.2018.09.010_bib0070","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1128\/MCB.00686-12","article-title":"Multiple Cancer testis antigens function to support tumor cell mitotic fidelity","volume":"32","author":"Cappell","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0075","first-page":"5544","article-title":"An overview of the MAGE gene family with the identification of all human members of the family","volume":"61","author":"Chomez","year":"2001","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2018.09.010_bib0080","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.18632\/oncotarget.2084","article-title":"Notch signalling drives multiple myeloma indiced osteoclastogenesis","volume":"5","author":"Colombo","year":"2014","journal-title":"Oncotarget"},{"issue":"29","key":"10.1016\/j.critrevonc.2018.09.010_bib0085","doi-asserted-by":"crossref","first-page":"26826","DOI":"10.18632\/oncotarget.5025","article-title":"Notch signaling deregulation in multiple myeloma: a rational molecular target","volume":"6","author":"Colombo","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.critrevonc.2018.09.010_bib0090","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.4049\/jimmunol.178.5.3307","article-title":"Cancer\/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis","volume":"178","author":"Condomines","year":"2007","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.09.010_bib0095","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/leu.2008.43","article-title":"MAGE-C1\/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma","volume":"22","author":"Curioni-Fontecedro","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.09.010_bib0100","doi-asserted-by":"crossref","first-page":"e95136","DOI":"10.1371\/journal.pone.0095136","article-title":"Oncogenic functions of the cancer-testis antigen ssx on the proliferation, survival, and signaling pathways of cancer cells","volume":"9","author":"D\u2019arcy","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0105","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/257695","article-title":"Cancer\/testis antigen mage-C1\/CT7: new target for multiple myeloma therapy","author":"De Carvalho","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.09.010_bib0110","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1128\/MCB.19.11.7327","article-title":"DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-Rich promoter","volume":"19","author":"De Smet","year":"1999","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.09.010_bib0115","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1078-0432.CCR-14-3175","article-title":"Cancer neoantigens and applications for immunotherapy","volume":"22","author":"Desrichard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0120","first-page":"9","article-title":"Expression of cancer\/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease","volume":"3","author":"Dhodapkar","year":"2003","journal-title":"Cancer Immun."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.09.010_bib0125","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molcel.2010.08.029","article-title":"MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases","volume":"39","author":"Doyle","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0130","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting symptoms","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.09.010_bib0135","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.09.010_bib0140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.hoc.2007.08.010","article-title":"Prognostic factors and staging in multiple myeloma","volume":"21","author":"Fonseca","year":"2007","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens:putative function,regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol. Oncol."},{"issue":"Suppl. (February)","key":"10.1016\/j.critrevonc.2018.09.010_bib0150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4161\/hv.7.0.14573","article-title":"Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses","volume":"7","author":"Geldmacher","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"18","key":"10.1016\/j.critrevonc.2018.09.010_bib0155","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0160","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2005-02-0563","article-title":"CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden","volume":"106","author":"Goodyear","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2018.09.010_bib0165","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"39","key":"10.1016\/j.critrevonc.2018.09.010_bib0170","doi-asserted-by":"crossref","first-page":"42028","DOI":"10.18632\/oncotarget.5973","article-title":"Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E","volume":"6","author":"Hao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2004.1.237","article-title":"Richardson P. Multiple myeloma","author":"Harousseau","year":"2004","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"11","key":"10.1016\/j.critrevonc.2018.09.010_bib0180","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"51","key":"10.1016\/j.critrevonc.2018.09.010_bib0185","doi-asserted-by":"crossref","first-page":"20422","DOI":"10.1073\/pnas.0810777105","article-title":"Genome-wide analysis of cancer\/testis gene expression","volume":"105","author":"Hofmann","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.critrevonc.2018.09.010_bib0190","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","article-title":"The immunotherapy era of myeloma: monoclonal antibodies, vaccines and adoptive t cell therapies","volume":"128","author":"Hogos","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.09.010_bib0195","doi-asserted-by":"crossref","first-page":"e1078965","DOI":"10.1080\/2162402X.2015.1078965","article-title":"A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer","volume":"5","author":"Jagadish","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0200","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1073\/pnas.220413497","article-title":"Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers","volume":"97","author":"Jager","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.09.010_bib0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Jungbluth","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-2407-13-144","article-title":"Derepression of Cancer\/Testis Antigens in cancer is associated with distinct patterns of DNA Hypomethylation","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0215","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.12194","article-title":"Next-generation sequencing-feasibility and practicality in haematology","volume":"160","author":"Kohlmann","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0220","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2005.1.346","article-title":"Early genetic events provide the basis for a clinical classification of multiple myeloma","author":"Kuehl","year":"2005","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.09.010_bib0225","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2018.09.010_bib0230","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1093\/nar\/gkh735","article-title":"MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription","volume":"32","author":"Laduron","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0235","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2017.06.015","article-title":"Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells","volume":"403","author":"Lee","year":"2017","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.09.010_bib0240","article-title":"Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients","volume":"10","author":"Lendvai","year":"2010","journal-title":"Cancer Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.09.010_bib0245","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.18632\/oncotarget.22973","article-title":"MAGE-A11 is activated through TFCP2\/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth","volume":"9","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0250","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.09.010_bib0255","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.09.010_bib0260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","article-title":"Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy","volume":"9","author":"Mazzone","year":"2017","journal-title":"Clin. Epigenetics"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.09.010_bib0265","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1074\/jbc.M112.428409","article-title":"Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers","volume":"288","author":"Minges","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.09.010_bib0270","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5045\/br.2013.48.4.242","article-title":"Next generation sequencing: new tools in immunology and hematology","volume":"48","author":"Mori","year":"2013","journal-title":"Blood Res."},{"issue":"37","key":"10.1016\/j.critrevonc.2018.09.010_bib0275","doi-asserted-by":"crossref","first-page":"34287","DOI":"10.1074\/jbc.M204973200","article-title":"An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12","volume":"277","author":"Morishima","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.critrevonc.2018.09.010_bib0280","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-10-1820","article-title":"MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin","volume":"17","author":"Nardiello","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.09.010_bib0285","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/bjc.2016.187","article-title":"The cancer\/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas","volume":"115","author":"Nettersheim","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.09.010_bib0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejmhg.2017.09.004","article-title":"Modified T-cells (using TCR and CTAs), chimeric antigen receptor (CAR) and other molecular tools in recent gene therapy","volume":"19","author":"Odiba","year":"2017","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.09.010_bib0295","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","article-title":"Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer","volume":"2","author":"Odunsi","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2018.09.010_bib0300","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1182\/blood-2008-07-170282","article-title":"The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.09.010_bib0305","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.187.8.1163","article-title":"New paths in human Cancer serology","volume":"187","author":"Old","year":"1998","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.09.010_bib0310","doi-asserted-by":"crossref","first-page":"e83212","DOI":"10.1371\/journal.pone.0083212","article-title":"Centrosomal localisation of the cancer\/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells","volume":"8","author":"Pagotto","year":"2013","journal-title":"PLos One"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0315","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO-RQPCR for minimal residual disease evaluation in multiple myeloma. A comparitive with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2018.09.010_bib0320","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","article-title":"Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells","volume":"20","author":"Rapoport","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.09.010_bib0325","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0330","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semcdb.2014.03.001","article-title":"The role of E3 ligases in the ubiquitin-dependant regulation of spermatogenesis","volume":"0","author":"Richburg","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.09.010_bib0335","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1357-4310(97)01081-2","article-title":"Serological analysis of human tumor antigens: molecular definition and implications","volume":"3","author":"Sahin","year":"1997","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0340","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.09.010_bib0345","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is de\ufb01ned by deregulated expression of genes mapping to chromosome1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2018.09.010_bib0350","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00432-016-2231-3","article-title":"Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients","volume":"142","author":"Shires","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.09.010_bib0355","article-title":"Cancer\/Testis antigen expression panel incorporating MAGEC1 and BAGE2 predicts multiple myeloma disease stage and severity","volume":"4","author":"Shires","year":"2016","journal-title":"J. Hematol. Thromboembolic Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.09.010_bib0360","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00002371-200201000-00002","article-title":"Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma","volume":"25","author":"Sigalotti","year":"2002","journal-title":"J. Immunother."},{"issue":"16","key":"10.1016\/j.critrevonc.2018.09.010_bib0365","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","article-title":"Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2 \u25a1 -deoxycytidine","volume":"1","author":"Sigalotti","year":"2004","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.09.010_bib0370","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0375","unstructured":"https:\/\/www.genenames.org\/cgi-bin\/genefamilies\/set\/1136."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0380","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-11-2127","article-title":"Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer","volume":"71","author":"Smith","year":"2011","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.09.010_bib0385","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.leukres.2014.09.001","article-title":"Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts","volume":"38","author":"Srivastava","year":"2014","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.09.010_bib0390","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4161\/onci.20686","article-title":"Cancer testis antigens: a new paradigm for cancer therapy","volume":"1","author":"Suri","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0395","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"200","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/jcm6100091","article-title":"Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation","volume":"6","author":"Takamatsu","year":"2017","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0405","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.cji.0000175685.36239.e5","article-title":"SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs","volume":"28","author":"Taylor","year":"2005","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.09.010_bib0410","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1349-7006.2008.00738.x","article-title":"MAGE-C1\/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome","volume":"99","author":"Tinguely","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0415","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.hoc.2007.08.004","article-title":"Molecular pathogenesis of multiple myeloma","volume":"21","author":"Tonon","year":"2007","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.09.010_bib0420","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells","volume":"102","author":"van Baren","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"5038","key":"10.1016\/j.critrevonc.2018.09.010_bib0425","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.critrevonc.2018.09.010_bib0430","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"Van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2018.09.010_bib0435","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3324\/haematol.2010.037978","article-title":"Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy","volume":"96","author":"Van Duin","year":"2011","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.critrevonc.2018.09.010_bib0440","article-title":"Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use","volume":"7","author":"Van Laar","year":"2014","journal-title":"BMC Med. Genomics"},{"issue":"10","key":"10.1016\/j.critrevonc.2018.09.010_bib0445","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1i s highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.09.010_bib0450","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1535-7163.MCT-12-0782","article-title":"Endoplasmic reticulum stress and the unfolded protein response: targeting the achilles heel of multiple myeloma","volume":"12","author":"Vincenz","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0455","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1476-4598-9-226","article-title":"Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia","volume":"9","author":"Wadelin","year":"2010","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.09.010_bib0460","first-page":"3513","article-title":"Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0465","first-page":"1766","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2032-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2015.08.002","article-title":"The MAGE protein family and cancer","volume":"37","author":"Weon","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0475","doi-asserted-by":"crossref","first-page":"e0120734","DOI":"10.1371\/journal.pone.0120734","article-title":"The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma","volume":"10","author":"Wienand","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.critrevonc.2018.09.010_bib0480","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1158\/0008-5472.CAN-07-1478","article-title":"MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0485","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.09.010_bib0490","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1128\/MCB.20.7.2400-2410.2000","article-title":"SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC to facilitate NotchIC function","volume":"20","author":"Zhou","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.09.010_bib0495","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1159\/000487353","article-title":"Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of P53 mediated pathway","volume":"45","author":"Zhu","year":"2018","journal-title":"Cell. Physiol. Biochem."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:27:33Z","timestamp":1760902053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818302671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":99,"alternative-id":["S1040842818302671"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.09.010","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of Cancer\/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}